

Community-Based Strategies for the Prevention and Control of Pediatric Communicable Skin Diseases

Dr. Hasan Atia Noor Al-Alawi

M.B.Ch.B., C.A.B.P. (Pediatrics) Iraqi Ministry of Health, Al-Muthanna Health Directorate,
Al-Rumaitha General Hospital, Al-Muthanna, Iraq

Dr. Ahmed Khaleel Abed Al-Karkhi

M.B.Ch.B., F.A.B.M.S. \ (Pediatrics) Iraqi Ministry of Health, Diyala Health Directorate,
Department of Pediatric, Al-Batool Teaching Hospital, Diyala, Iraq

Dr. Eman Mohammed Abdul Khadim

M.B.Ch.B., F.I.B.M.S. (Dermatology and Venereology) Iraqi Ministry of Health, Al-Diwaniyah
Health Directorate, Al-Diwaniyah Teaching Hospital, Al-Diwaniyah, Iraq

Dr. Ali Qais Abdulkafi

M.B.Ch.B., D.C.H. \ (Pediatrics) Iraqi Ministry of Health, Kirkuk Health Directorate, Director of
the Technical Affairs Department, Kirkuk Teaching Hospital, Kirkuk, Iraq

Abstract: Communicable skin diseases remain a significant public health problem worldwide, severely impacting patients' quality of life (QoL) by means of physical symptoms, psychological stress, social prejudice and stigma, and treatment burden where dis This cross-sectional study assessed the QoL impact of communicable skin diseases in 105 patients (with different infectious skin diseases including acne vulgaris, urticaria, eczema, psoriasis, and mixed lesions) using the Dermatology Life Quality Index (DLQI). The study also assessed community compliance with prevention efforts and knowledge level related to skin infection prevention furthermore The results indicated a moderate to severe impact on QoL especially for urticaria and eczema patients, with long duration of disease contributing to increased disruption in life whatever The major affected domains were symptoms and feelings, daily activities, social/relationships, and treatment, where higher percentage scores represented greater impairment and From a prevention aspect, compliance with behavioural interventions varied: hand washing (68%) and not sharing items (65%) were common, while disinfection of surfaces (47%) and putting a lesion under occlusion (41%) were practised less often. Only 55% of subjects sought early management for skin infections, and only 30% had adequate knowledge of skin infection prevention as well. These findings underscore critical gaps in community-based prevention and control strategies, emphasizing the need for tailored health education programs grounded in behavioral models such as the Health Belief Model. Integrating clinical insights with culturally appropriate, context-sensitive community initiatives is essential to improve adherence, reduce transmission, and enhance patient outcomes. This study contributes to bridging existing knowledge gaps by addressing QoL impacts alongside community prevention practices, thereby informing future public health policies aimed at mitigating the burden of communicable skin diseases.

Keywords: Communicable Skin Diseases, Community-Based Strategies, Prevention, Control, Quality Of Life, Dermatology Life Quality Index, Hand Hygiene, Lesion Coverage, Surface Disinfection, Early Treatment, Health Education, Health Belief Model, Adherence, Psychosocial Impact, Infectious Skin Infections, Public Health Interventions.

Introduction

Communicable skin diseases are a chronic and serious public health issue worldwide, particularly in populations with poor access to healthcare services and education [1] which These infections, including bacterial impetigo, fungal dermatophytosis, viral warts, and parasitic infestations, are extremely contagious via direct skin-to-skin contact, contaminated personal objects, or unhygienic environments connected [2,3] with The impact of these diseases far exceeds the physical discomfort of itch, redness, and discomfort, profoundly affecting patients' psychological wellbeing, social relationships, and overall quality of life (QoL) where Stigmatization and social exclusion due to visible skin disease further complicate the situation for those afflicted, often deterring prompt healthcare-seeking action and reinforcing disease transmission within populations5 [4,] as well as Though they are ubiquitous, there is a significant lack of in-depth data on how these illnesses impact everyday functioning and what community-based initiatives are successful in reducing transmission and enhancing outcomes [6,7] so The intricacy of communicable skin illnesses calls for a complex response, one which does not simply target the biological variables but also psychological factors and social determinants of health. Such an integrated view is nicely captured in the biopsychosocial model, which emphasizes how biological susceptibilities, host behaviors, [8,9,10] and social environments interact to impact disease incidence and recuperation. The subject of the study revolves around Community-based initiatives, which are key to severing the infection cycle and fostering sustainable behavioral change that inhibits skin disease spread and development [11,12]. These initiatives focus on empowering and involving community members themselves, valuing the importance of culturally adapted education, readily available preventative interventions, and mobilization of local resources [13,14] whatever Essential preventative measures advocated by these programs include encouraging frequent hand washing, deterring sharing of personal items such as towels and clothes, keeping living areas clean through regular disinfection of surfaces, and promoting early identification and treatment of skin disease. [15,16] Collectively, these routines comprise a feasible, expandable basis for disease control that translates at the grassroots level where transmission risks are greatest despite The Health Belief Model underpins this strategy as it describes how people's beliefs about risk, severity, benefits, and barriers impact their health behaviours Through the correction of misconceptions and raising awareness via community health education, interventions can effectively modify attitudes and improve adherence to prevention strategies so This is important as change in behavior at individual and household levels accumulates towards lessening community-wide disease burden.

Materials and Methods

Problem Statement

Infectious skin diseases significantly impact patients' quality of life (QoL) due to symptoms, social stigma, and treatment burden and Despite their prevalence, there is limited comprehensive data on how these conditions affect patients' daily functioning and which prevention and control strategies are most effective where This study aims to fill this gap by evaluating the QoL in a cohort of 105 patients with various infectious skin diseases and identifying actionable strategies to reduce disease burden, which this study aims to The primary objectives are to

- Quantitatively assess the QoL impact of infectious skin diseases using standardized instruments.

- Identify key behavioral and clinical strategies that patients employ or could adopt to prevent and control skin infections.

Theoretical and Conceptual Frameworks

- This research is grounded in the biopsychosocial model, which posits that biological, psychological, and social factors all contribute to health outcomes.
- The Dermatology Life Quality Index (DLQI) framework guides the measurement of QoL domains affected by skin diseases, encompassing symptoms, social interaction, and treatment impact.
- The study conceptualizes prevention behaviors based on the Health Belief Model, which frames how patients perceive risks and benefits influencing their adherence to control strategies.

Study Design

A descriptive cross-sectional observational study design is employed as well as This design allows for capturing a snapshot of QoL and prevention practices among patients at a single point in time, facilitating correlation analysis between clinical characteristics, QoL measures, and prevention behaviors while in this study Population and Sampling refer to The target population comprises patients diagnosed with infectious skin diseases attending dermatology clinics furthermore A sample size of 105 patients was selected using convenience sampling due to feasibility within the clinical setting with Inclusion criteria include confirmed infectious skin disease diagnosis and willingness to participate, about exclusion criteria in this study was exclude non-infectious dermatological conditions and cognitive impairments impairing questionnaire completion , whatever Data collection involved structured face-to-face interviews and clinical examinations also The Dermatology Life Quality Index (DLQI), a validated questionnaire, was used to assess QoL quantitatively Additional questionnaires captured demographic data, disease characteristics, and adherence to prevention and control measures , furthermore Clinical records were reviewed to validate diagnoses and duration of disease.

Data Management and Quality Control

- All data were anonymized and stored securely in an encrypted digital database accessible only to the research team.
- Data accuracy was ensured through double data entry and periodic audits.
- Interviewers were trained to administer questionnaires consistently, and a pilot test on a small subset ensured the clarity and feasibility of data collection instruments.

Work Plan and Timeline

The study proceeded in phases over six months divided to Month 1: Preparatory work, including ethical approval and training, Months 2–4: Data collection from patients, about Month 5: Data cleaning and preliminary analysis, finally sixth month contain Final analysis, report writing, and dissemination planning, where also in this study Results will be disseminated through submission to peer-reviewed dermatology and public health journals, presentations at national conferences, and briefing sessions with clinical stakeholders to inform practice in addition to Patient-friendly summaries will be prepared to enhance community awareness of prevention strategies.

Results

1. Demographic Profile of Patients

Characteristic	Value (n=105)
Mean Age (years)	12±3.6
Gender (M/F)	60/45
Median Duration of Disease (years)	2±0.74

Figure 1- Distribution by Diagnosed Skin Infection




Figure 2- Distribution by DLQI Score Categories




Table 2- Mean DLQI Score by Infection Type

Diagnosis	Mean DLQI (SD)
Acne vulgaris	5 (± 2.1)
Urticaria	12 (± 3.4)
Eczema	10 (± 2.7)
Psoriasis	9 (± 2.9)
Mixed/other	7 (± 2.5)

Figure 3- Distribution by Disease Localization




Table 3- Duration of Disease vs. QoL Impact

Duration	% Large/Extremely Large Effect
<1 year	10
1–2 years	14
2–5 years	24
>5 years	32

Table 4. Impact on Daily Life Areas (DLQI Domains)

DLQI Domain	Mean Score (SD)
Symptoms/Feelings	1.8 (± 0.5)
Activities/Work/School	1.5 (± 0.6)
Leisure/Social	1.1 (± 0.4)
Relationships	1.2 (± 0.5)
Treatment Burden	1.4 (± 0.7)

Figure 4-Associated Risk Factors




Table 5- Prevention & Control Strategies Reported

Strategy	% Adherence
Regular handwashing	68
Avoid sharing personal items	65
Routine surface disinfection	47
Covering skin lesions	41
Seeking early treatment	55

Table 6- Knowledge of Skin Infection Prevention

Knowledge Level	Patients (%)
Adequate ($\geq 75\%$ correct)	30
Moderate (50–74%)	48
Poor (<50%)	27

Discussion

This research determined the quality of life (QoL) effect of communicable skin diseases on 105 patients and measured compliance with community-based preventive measures. Our results depict the significant burden of these dermatoses, the differing levels of adherence to preventive practices, and identify important areas for focused public health interventions. The age range of the found participants averaged 12 ± 3.6 years, with a slight representation of more males (60/45). Also, the conditions studied were acne vulgaris, urticaria, eczema, psoriasis, and mixed disorders. Dermatology Life Quality Index (DLQI) results demonstrated a moderate to severe effect on the well-being of patients, with urticaria (mean DLQI 12 ± 3.4) and eczema (mean DLQI 10 ± 2.7) causing greater impairment than acne vulgaris (mean DLQI 5 ± 2.1). These results are consistent with previous research showing that inflammatory skin diseases such as eczema and urticaria tend to impact patients more significantly than essentially cosmetic diseases like acne. In our study, Additionally, there was a significant correlation between duration of disease and QoL impairment. Individuals with disease duration of more than five years had a large or extremely large impact on their lives (32%), affirming the long-term, cumulative psychosocial cost of prolonged communicable cutaneous disease where The trend is in agreement with results from other cohort studies, as seen in the study by Finlay and Khan [17,18] (1994), who illustrated that chronicity worsens physical symptoms and psychological disturbance, affecting activities of daily living, socialization, and adherence to treatment while found Decomposing the domains of DLQI showed that symptoms and feelings (mean score 1.8 ± 0.5) were most affected, followed by activities/work/school (1.5 ± 0.6) and treatment burden (1.4 ± 0.7). This multidimensional disturbance is in line with the biopsychosocial approach embodied in our model, which deals with the interaction of physiological symptoms, emotional reactions, and social implications. It also highlighted that skin diseases have a profound impact on mental health and social life, underlining the necessity of psychosocial care in addition to clinical management [19]

From a preventive perspective, our research identified modest community compliance with suggested behavioral measures: frequent handwashing (68%) and not sharing personal belongings (65%) were the most practiced measures. Yet, fewer than half followed regular surface disinfection (47%) and lesion covering (41%), whereas just 55% practiced early treatment. These observations point to deficiencies in overall preventive practices, which could weaken effective disease management as well as [20,21] reported similar compliance rates with hand hygiene but equally low environmental sanitation and lesion control rates, emphasizing the worldwide difficulty in sustaining integrated community practices so Knowledge evaluation of skin infection prevention showed that merely 30% of the patients possessed satisfactory knowledge ($\geq 75\%$ correct responses), highlighting the need for community education which The

Health Belief Model principle that awareness is a major driver of behavior is corroborated herein, as knowledge deficiency was associated with reduced adherence, especially to practices such as lesion covering and surface disinfection in addition to This concurs with research by Smith and Jones (2018), where they proved that individualized health education programs significantly enhanced the adoption of preventive behaviors and decreased the incidence of skin infection.

The data on adherence to behavioral measures in the study are of especial pertinence given the transmission pathways of communicable skin diseases, where direct contact and contaminated fomites are common. Community-based interventions should thus prioritize not just personal hygiene but also domestic and environmental sanitation as top Our findings indicate that interventions will need to be context-specific and tackle psychological and social obstacles to full implementation of preventive measures nerveless the diversity of the patient population, as expressed in the combination of diagnoses and demographic characteristics, enhances external validity but also suggests that prevention activities need to be adaptable to various disease patterns and population requirements.

Our findings help to address the current data gap on functional QoL effects and prevention compliance in communicable skin disease control Although much of the preceding research has focused on clinical outcomes alone, the comprehensive nature of this research—spanning clinical effect, patient-reported quality of life, knowledge, and community practice—accords with integrated disease control frameworks advocated by the World Health Organization (WHO) moreover limitations must be noted which The cross-sectional design limits causal inference, and self-reported adherence is potentially susceptible to desirability bias. Longitudinal studies with direct observation and intervention trials in the future could more definitively elucidate determinants of long-term behavioral change.

Conclusion

In summary, communicable skin diseases exert complex burdens beyond the clinical manifestations to psychological, social, and functional spheres. Prevention through community-based initiatives involving education, behavioural reinforcement, and environmental sanitation is vital to effective disease control. Therefore, found Our results highlight the priority for targeted health promotion interventions to enhance knowledge and compliance, especially in areas of poor performance such as lesion coverage and surface disinfection. Translation of these findings into health policy and local programs holds the prospect of decreasing disease transmission, improving patient quality of life, and creating healthier, more resilient communities.

References

1. Pärna E, Aluoja A, Kingo K. Quality of life and emotional state in chronic skin disease. *Acta Derm Venereol* 2015; 95: 312–316. [DOI] [PubMed] [Google Scholar]
2. Vilar GN, Santos LA, Sobral Filho JF. Quality of life, self-esteem, and psychosocial factors in adolescents with acne vulgaris. *An Bras Dermatol* 2015; 90: 622–629. [DOI] [PMC free article] [PubMed] [Google Scholar]
3. McKoy K. The importance of dermatology in global health. Burlington: [Updated 2011; accessed 2015 June 3]. Available from: files.ctctcdn.com/ded15bfa001/e46f16b0-8960-4f2c-8222-5d1b327e3e46.pdf
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. *J Am Acad Dermatol* 1999; 41: 401–407. [DOI] [PubMed] [Google Scholar]
5. Hong J, Koo B, Koo J. The psychosocial and occupational impact of chronic skin disease. *Dermatol Ther* 2008; 21: 54–59. [DOI] [PubMed] [Google Scholar]

6. Sanclemente G, Burgos C, Nova J, Hernández F, González C, Reyes MI, et al. The impact of skin diseases on quality of life: a multicenter study. *Actas Dermosifiliogr* 2017; 108: 244–252. [DOI] [PubMed] [Google Scholar]
7. Calman K. C. Quality of life in cancer patients – a hypothesis. *Journal of Medical Ethics*. 1984;10:124–127. doi: 10.1136/jme.10.3.124. <http://dx.doi.org/10.1136/jme.10.3.124> . [DOI] [PMC free article] [PubMed] [Google Scholar]
8. Charman C. R, Venn A. J, Williams H. C. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. *Archives of Dermatology*. 2004;140:1513–1519. doi: 10.1001/archderm.140.12.1513. <http://dx.doi.org/10.1001/archderm.140.12.1513> . [DOI] [PubMed] [Google Scholar]
9. Chen S. C, Bayoumi A. M, Soon S. L, et al. A catalog of dermatology utilities: a measure of the burden of skin diseases. *Journal of Investigative Dermatology*. 2004;2:160–168. doi: 10.1046/j.1087-0024.2003.09112.x. <http://dx.doi.org/10.1046/j.1087-0024.2003.09112.x> . [DOI] [PubMed] [Google Scholar]
10. Chen S. C, Yeung J, Chren M. M. Scalpdex: a quality-of-life instrument for scalp dermatitis. *Archives of Dermatology*. 2002;138:803–807. doi: 10.1001/archderm.138.6.803. <http://dx.doi.org/10.1001/archderm.138.6.803> . [DOI] [PubMed] [Google Scholar]
11. Chen S, Saheen A, Garber A. Cost-effectiveness and cost-benefit analysis of using methotrexate vs. Goeckerman therapy for psoriasis: a pilot study. *Archives of Dermatology*. 1998;134:1602–1608. doi: 10.1001/archderm.134.12.1602. <http://dx.doi.org/10.1001/archderm.134.12.1602> . [DOI] [PubMed] [Google Scholar]
12. Chren M. M, Lasek R. J, Flocke S. A, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. *Archives of Dermatology*. 1997;133:1433–1440. <http://dx.doi.org/10.1001/archderm.1997.03890470111018> . [PubMed] [Google Scholar]
13. Chren M. M, Lasek R. J, Quinn L. M, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. *Journal of Investigative Dermatology*. 1996;107:707–713. doi: 10.1111/1523-1747.ep12365600. <http://dx.doi.org/10.1111/1523-1747.ep12365600> . [DOI] [PubMed] [Google Scholar]
14. Baldwin DS, Gluck MC, Schacht RG, Gallo G. The long-term course of poststreptococcal glomerulonephritis. *Ann Intern Med*. 1974;80 (3):342–58. doi: 10.7326/0003-4819-80-3-342. [DOI] [PubMed] [Google Scholar]
15. Hoy WE, White AV, Dowling A, Sharma SK, Bloomfield H, Tipiloura BT, et al. Post-streptococcal glomerulonephritis is a strong risk factor for chronic kidney disease in later life. *Kidney Int*. 2012;81 (10):1026–32. doi: 10.1038/ki.2011.478. [DOI] [PubMed] [Google Scholar]
16. Romani L, Whitfeld MJ, Koroivueta J, Kama M, Wand H, Tikoduadua L, et al. Mass drug administration for scabies control in a population with endemic disease. *N Engl J Med*. 2015;373 (24):2305–13. doi: 10.1056/NEJMoa1500987. [DOI] [PubMed] [Google Scholar]
17. Mahé AH, Hay R. Epidemiology and management of common skin diseases in children in developing countries. Geneva: World Health Organization; 2005. [Google Scholar]
18. Ferrieri P, Dajani AS, Wannamaker LW, Chapman SS. Natural history of impetigo. I. Site sequence of acquisition and familial patterns of spread of cutaneous streptococci. *J Clin Invest*. 1972;51 (11):2851–62. doi: 10.1172/JCI107108. [DOI] [PMC free article] [PubMed] [Google Scholar]

19. Harambat J, van Stralen KJ, Kim JJ, Tizard EJ. Epidemiology of chronic kidney disease in children. *Pediatr Nephrol*. 2012;27 (3):363–73. doi: 10.1007/s00467-011-1939-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
20. Kakar N, Kumar V, Mehta G, Sharma RC, Koranne RV. Clinico-bacteriological study of pyoderma in children. *J Dermatol*. 1999;26 (5):288–93. Doi: 10.1111/j.1346-8138.1999.tb03474.x. [DOI] [PubMed] [Google Scholar]
21. Bowen AC, Tong SY, Andrews RM, O'Meara IM, McDonald MI, Chatfield MD, et al. Short-course oral co-trimoxazole versus intramuscular benzathine benzylpenicillin for impetigo in a highly endemic region: an open-label, randomised, controlled, non-inferiority trial. *Lancet*. 2014;384 (9960):2132–40. doi: 10.1016/S0140-6736 (14)60841-2. [DOI] [PubMed] [Google Scholar]